Medifast (NYSE:MED) Releases Q1 2025 Earnings Guidance

Medifast (NYSE:MED) issued an update on its first quarter 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of -0.500-0.000 for the period, compared to the consensus estimate of -0.190. The company issued revenue guidance of $100.0 million-$120.0 million, compared to the consensus revenue estimate of $130.8 million.

Medifast Stock Down 11.1 %

Shares of NYSE:MED opened at $14.35 on Thursday. The firm has a market capitalization of $156.96 million, a P/E ratio of 79.71 and a beta of 1.14. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.55 and a current ratio of 3.11. The stock has a 50 day moving average price of $16.49 and a 200-day moving average price of $18.02. Medifast has a 52-week low of $14.16 and a 52-week high of $49.90.

Medifast (NYSE:MED) last posted its quarterly earnings data on Tuesday, February 18th. The specialty retailer reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.26. Medifast had a return on equity of 10.66% and a net margin of 0.35%. The business had revenue of $119.00 million during the quarter, compared to the consensus estimate of $114.25 million. As a group, equities research analysts anticipate that Medifast will post 0.51 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, DA Davidson cut their price objective on shares of Medifast from $17.00 to $16.50 and set a “neutral” rating on the stock in a report on Wednesday.

About Medifast

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.